This trial is testing a new drug, retifanlimab, for endometrial cancer that has progressed after platinum-based chemotherapy. It will be given as monotherapy or in combination with other immunotherapy or targeted agents.
1 Primary · 13 Secondary · Reporting Duration: up to 3.5 years
Experimental Treatment
300 Total Participants · 6 Treatment Groups
Primary Treatment: retifanlimab · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: